LILRB3

Summary

LILRB3 (leukocyte immunoglobulin like receptor B3, HGNC:6607) is a protein-coding gene on chromosome 19q13.42, encoding Leukocyte immunoglobulin-like receptor subfamily B member 3 (O75022). May act as receptor for class I MHC antigens.

This gene is a member of the leukocyte immunoglobulin-like receptor (LIR) family, which is found in a gene cluster at chromosomal region 19q13.4. The encoded protein belongs to the subfamily B class of LIR receptors which contain two or four extracellular immunoglobulin domains, a transmembrane domain, and two to four cytoplasmic immunoreceptor tyrosine-based inhibitory motifs (ITIMs). The receptor is expressed on immune cells where it binds to MHC class I molecules on antigen-presenting cells and transduces a negative signal that inhibits stimulation of an immune response. It is thought to control inflammatory responses and cytotoxicity to help focus the immune response and limit autoreactivity. Multiple transcript variants encoding different isoforms have been found for this gene.

Source: NCBI Gene 11025 — RefSeq curated summary.

At a glance

• GWAS associations: 4
• Clinical variants (ClinVar): 127 total
• MANE Select transcript: NM_006864

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:6607
Approved symbol	LILRB3
Name	leukocyte immunoglobulin like receptor B3
Location	19q13.42
Locus type	gene with protein product
Status	Approved
Aliases	LIR-3, HL9, ILT5, LIR3, CD85a, PIRB, PIR-B
Ensembl gene	ENSG00000204577
Ensembl biotype	protein_coding
OMIM	604820
Entrez	11025

Gene structure

Transcript identifiers

Ensembl transcripts: 11 — 6 protein_coding, 3 retained_intron, 1 nonsense_mediated_decay, 1 protein_coding_CDS_not_defined

ENST00000245620, ENST00000346401, ENST00000391750, ENST00000414379, ENST00000436504, ENST00000445347, ENST00000460208, ENST00000468668, ENST00000469273, ENST00000861602, ENST00000861603

RefSeq mRNA: 3 — MANE Select: NM_006864 NM_001081450, NM_001320960, NM_006864

CCDS: CCDS33105, CCDS46175

Canonical transcript exons

ENST00000445347 — 13 exons

Exon	Start	End
ENSE00001509644	54216278	54217239
ENSE00001594089	54222943	54223007
ENSE00002475389	54221828	54222130
ENSE00002519447	54222747	54222782
ENSE00003462434	54222278	54222562
ENSE00003463275	54220528	54220830
ENSE00003473961	54220155	54220205
ENSE00003485026	54218763	54218838
ENSE00003540500	54219129	54219245
ENSE00003541022	54218361	54218413
ENSE00003576880	54218645	54218682
ENSE00003580371	54217319	54217474
ENSE00003650808	54221083	54221379

Expression profiles

Bgee: expression breadth ubiquitous, 133 present calls, max score 99.19.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.1978 / max 18.2486, expressed in 105 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
182614	3.6357	273
182615	0.1978	105

Top tissues by expression

133 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
blood	UBERON:0000178	99.19	gold quality
granulocyte	CL:0000094	97.55	gold quality
leukocyte	CL:0000738	97.36	gold quality
monocyte	CL:0000576	97.35	gold quality
spleen	UBERON:0002106	96.86	gold quality
upper lobe of left lung	UBERON:0008952	94.08	gold quality
vermiform appendix	UBERON:0001154	92.47	gold quality
right lung	UBERON:0002167	92.37	gold quality
bone marrow	UBERON:0002371	91.29	gold quality
bone marrow cell	CL:0002092	89.92	gold quality
lung	UBERON:0002048	88.89	gold quality
omental fat pad	UBERON:0010414	87.75	gold quality
right coronary artery	UBERON:0001625	85.73	gold quality
right lobe of liver	UBERON:0001114	85.36	gold quality
adipose tissue	UBERON:0001013	84.97	gold quality
left adrenal gland cortex	UBERON:0035825	83.90	gold quality
right adrenal gland	UBERON:0001233	83.76	gold quality
left adrenal gland	UBERON:0001234	83.29	gold quality
right adrenal gland cortex	UBERON:0035827	83.26	gold quality
subcutaneous adipose tissue	UBERON:0002190	82.87	gold quality
left uterine tube	UBERON:0001303	82.26	gold quality
gall bladder	UBERON:0002110	81.70	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	81.68	gold quality
descending thoracic aorta	UBERON:0002345	81.58	gold quality
liver	UBERON:0002107	81.42	gold quality
apex of heart	UBERON:0002098	81.33	gold quality
placenta	UBERON:0001987	80.47	gold quality
left coronary artery	UBERON:0001626	80.31	gold quality
ascending aorta	UBERON:0001496	80.02	gold quality
thoracic aorta	UBERON:0001515	79.93	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	9.56

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): RUNX3, SPI1

miRNA regulators (miRDB)

24 targeting LILRB3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5692B	100.00	71.32	2622
HSA-MIR-5692C	100.00	71.32	2622
HSA-MIR-512-3P	99.97	67.35	1049
HSA-MIR-6778-3P	99.96	67.29	2693
HSA-MIR-6753-3P	99.93	66.57	637
HSA-MIR-7107-3P	99.93	66.73	627
HSA-MIR-1200	99.71	70.42	1838
HSA-MIR-1208	99.70	68.28	1533
HSA-MIR-1303	99.65	69.77	1662
HSA-MIR-103A-1-5P	99.39	67.78	1545
HSA-MIR-103A-2-5P	99.39	67.72	1577
HSA-MIR-504-3P	99.30	67.18	1745
HSA-MIR-4279	99.19	66.70	2437
HSA-MIR-8077	99.17	66.67	862
HSA-MIR-6071	99.16	67.77	1780
HSA-MIR-367-5P	98.84	67.18	902
HSA-MIR-382-3P	98.83	67.10	1074
HSA-MIR-581	98.39	67.42	835
HSA-MIR-1304-3P	98.29	66.44	1207
HSA-MIR-6773-3P	98.17	65.51	1213
HSA-MIR-122-5P	97.23	64.92	1024
HSA-MIR-4445-5P	97.21	66.16	832
HSA-MIR-5702	96.68	68.21	958
HSA-MIR-8081	96.42	67.75	738

Literature-anchored findings (GeneRIF, showing 16)

• Coligation of LIR3 to LIR7 or to FcepsilonRI by means of a second monoclonal antibody significantly inhibited net histamine release, cysLT production, and IL-4 generation. LIR3 is counter-regulatory for both adaptive and innate receptors suggests. (PMID:15242876)
• Progenitor mast cells expressed cell surface inhibitory LILRB3. Mature cord-blood-derived mast cells had detectable mRNA encoding multiple LILRs, none were expressed on the cell surface. (PMID:17998301)
• LILRB3 is expressed on cultured osteoclast precursor cells derived from peripheral blood monocytes and plays a regulatory role in the development of osteoclasts. (PMID:18802077)
• Blockade of LILRB1 and LILRB3 receptors by monoclonal antibodies or short interfering RNA (siRNA) abrogated the specific antigen-presenting properties of dendritic cells, implying an important regulatory role of these molecules. (PMID:20631139)
• RPS9/LILRB3 (rs11666543) was associated with Takayasu arteritis. (PMID:25604533)
• Glatiramer Acetate Enhances Myeloid-Derived Suppressor Cell Function via Recognition of Paired Ig-like Receptor B. (PMID:30068593)
• Together, this study identified ILT5 as an immunosuppressive regulator during sepsis, which may provide potential therapeutic strategy for sepsis. (PMID:31250008)
• The Orphan Immune Receptor LILRB3 Modulates Fc Receptor-Mediated Functions of Neutrophils. (PMID:31915259)
• LILRB3 (ILT5) is a myeloid cell checkpoint that elicits profound immunomodulation. (PMID:32870822)
• Characterization of LILRB3 and LILRA6 allelic variants in the Japanese population. (PMID:33526815)
• KLRD1, FOSL2 and LILRB3 as potential biomarkers for plaques progression in acute myocardial infarction and stable coronary artery disease. (PMID:34271875)
• Epithelial cells remove precancerous cells by cell competition via MHC class I-LILRB3 interaction. (PMID:34686865)
• LILRB3 supports acute myeloid leukemia development and regulates T-cell antitumor immune responses through the TRAF2-cFLIP-NF-kappaB signaling axis. (PMID:35122056)
• Distinct frequency patterns of LILRB3 and LILRA6 allelic variants in Europeans. (PMID:36449053)
• LilrB3 is a putative cell surface receptor of APOE4. (PMID:36588123)
• Identification of the hybrid gene LILRB5-3 by long-read sequencing and implication of its novel signaling function. (PMID:38807600)

Cross-species orthologs

15 orthologs

Organism	Symbol	Gene ID
mus_musculus	Lilra6	ENSMUSG00000030427
mus_musculus	Pirb	ENSMUSG00000058818
mus_musculus	Lilra5	ENSMUSG00000070873
mus_musculus	Pira12	ENSMUSG00000074417
mus_musculus	Pira13	ENSMUSG00000074419
mus_musculus	Pira1	ENSMUSG00000081665
mus_musculus	Pira2	ENSMUSG00000089942
rattus_norvegicus	Lilra5	ENSRNOG00000027808
rattus_norvegicus	Lilrb3	ENSRNOG00000046683
rattus_norvegicus	Lilrb2	ENSRNOG00000054954
rattus_norvegicus	Lilrc2	ENSRNOG00000058087
rattus_norvegicus	Pirb	ENSRNOG00000058422
rattus_norvegicus	LOC134485274	ENSRNOG00000062907
rattus_norvegicus		ENSRNOG00000067708
rattus_norvegicus		ENSRNOG00000069029

Paralogs (25): GP6 (ENSG00000088053), LILRB1 (ENSG00000104972), LILRA1 (ENSG00000104974), LILRB5 (ENSG00000105609), A1BG (ENSG00000121410), KIR2DL1 (ENSG00000125498), LILRB2 (ENSG00000131042), IGSF1 (ENSG00000147255), LAIR2 (ENSG00000167618), KIR3DL1 (ENSG00000167633), OSCAR (ENSG00000170909), FCAR (ENSG00000186431), LILRB4 (ENSG00000186818), LILRA5 (ENSG00000187116), KIR2DL4 (ENSG00000189013), VSTM1 (ENSG00000189068), NCR1 (ENSG00000189430), KIR2DS4 (ENSG00000221957), LILRA4 (ENSG00000239961), LILRA2 (ENSG00000239998), KIR3DL2 (ENSG00000240403), KIR3DL3 (ENSG00000242019), KIR2DL3 (ENSG00000243772), LILRA6 (ENSG00000244482), TARM1 (ENSG00000248385)

Protein

Protein identifiers

Leukocyte immunoglobulin-like receptor subfamily B member 3 — O75022 (reviewed: O75022)

Alternative names: CD85 antigen-like family member A, Immunoglobulin-like transcript 5, Monocyte inhibitory receptor HL9

All UniProt accessions (4): C9JWL8, F8W6G6, F8WD89, O75022

UniProt curated annotations — full annotation on UniProt →

Function. May act as receptor for class I MHC antigens. Becomes activated upon coligation of LILRB3 and immune receptors, such as FCGR2B and the B-cell receptor. Down-regulates antigen-induced B-cell activation by recruiting phosphatases to its immunoreceptor tyrosine-based inhibitor motifs (ITIM).

Subunit / interactions. Interacts with LYN, PTPN6/SHP-1 and PTPN11/SHP-2.

Subcellular location. Cell membrane.

Tissue specificity. Detected in monocytes and B-cells.

Post-translational modifications. Phosphorylated on tyrosine residues by LYN. Phosphorylation at Tyr-595 and Tyr-625 is important for interaction with PTPN6/SHP-1 and PTPN11/SHP-2.

Domain organisation. Contains 3 copies of a cytoplasmic motif that is referred to as the immunoreceptor tyrosine-based inhibitor motif (ITIM). This motif is involved in modulation of cellular responses. The phosphorylated ITIM motif can bind the SH2 domain of several SH2-containing phosphatases, including PTPN6/SHP-1, resulting in the dephosphorylation of the downstream protein kinases SYK and BTK.

Miscellaneous. Belongs to the leukocyte receptor cluster (LRC) present on 19q13.4.

Isoforms (3)

UniProt ID	Names	Canonical?
O75022-1	1	yes
O75022-2	2
O75022-3	3

RefSeq proteins (3): NP_001074919, NP_001307889, NP_006855* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR003598	Ig_sub2	Domain
IPR003599	Ig_sub	Domain
IPR007110	Ig-like_dom	Domain
IPR013151	Immunoglobulin_dom	Domain
IPR013783	Ig-like_fold	Homologous_superfamily
IPR036179	Ig-like_dom_sf	Homologous_superfamily
IPR050412	Ig-like_Receptors_ImmuneReg	Family

Pfam: PF00047, PF13895

UniProt features (61 total): sequence conflict 17, sequence variant 13, compositionally biased region 5, glycosylation site 4, disulfide bond 4, domain 4, short sequence motif 3, region of interest 2, modified residue 2, topological domain 2, splice variant 2, signal peptide 1, chain 1, transmembrane region 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
8YOT	ELECTRON MICROSCOPY	2.48

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O75022-F1	74.31	0.52

Antibody-complex structures (SAbDab): 1 — 8YOT

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (2): 595, 625

Disulfide bonds (4): 49–98, 144–196, 245–296, 345–396

Glycosylation sites (4): 139, 280, 301, 340

Function

Pathways and Gene Ontology

Reactome pathways

5 pathways

ID	Pathway
R-HSA-198933	Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
R-HSA-6798695	Neutrophil degranulation
R-HSA-1280218	Adaptive Immune System
R-HSA-168249	Innate Immune System
R-HSA-168256	Immune System

MSigDB gene sets: 176 (showing top): GSE45365_CD8A_DC_VS_CD11B_DC_IFNAR_KO_DN, GOBP_MYELOID_CELL_DIFFERENTIATION, GOBP_NEGATIVE_REGULATION_OF_CELL_DEVELOPMENT, REACTOME_INNATE_IMMUNE_SYSTEM, GOBP_REGULATION_OF_OSTEOCLAST_DIFFERENTIATION, REACTOME_ADAPTIVE_IMMUNE_SYSTEM, GOBP_RESPONSE_TO_PEPTIDE, GOCC_SECRETORY_GRANULE, MODULE_45, MODULE_64, GOZGIT_ESR1_TARGETS_DN, MODULE_478, GOBP_MYELOID_LEUKOCYTE_DIFFERENTIATION, GOBP_REGULATION_OF_LEUKOCYTE_DIFFERENTIATION, GOBP_REGULATION_OF_IMMUNE_RESPONSE

GO Biological Process (7): adaptive immune response (GO:0002250), immune response-regulating signaling pathway (GO:0002764), defense response (GO:0006952), cell surface receptor signaling pathway (GO:0007166), cytokine-mediated signaling pathway (GO:0019221), negative regulation of osteoclast differentiation (GO:0045671), immune system process (GO:0002376)

GO Molecular Function (4): transmembrane signaling receptor activity (GO:0004888), inhibitory MHC class I receptor activity (GO:0032396), signaling receptor activity (GO:0038023), protein binding (GO:0005515)

GO Cellular Component (3): plasma membrane (GO:0005886), secretory granule membrane (GO:0030667), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-3 pathways:

Category	Pathways
Immune System	2
Adaptive Immune System	1
Innate Immune System	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
signal transduction	2
immune response	1
regulation of immune response	1
response to stress	1
cell surface receptor signaling pathway	1
cellular response to cytokine stimulus	1
negative regulation of myeloid leukocyte differentiation	1
osteoclast differentiation	1
regulation of osteoclast differentiation	1
biological_process	1
signaling receptor activity	1
MHC class I receptor activity	1
molecular transducer activity	1
binding	1
membrane	1
cell periphery	1
secretory granule	1
cytoplasmic vesicle membrane	1
bounding membrane of organelle	1
cellular anatomical structure	1

Protein interactions and networks

STRING

1296 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
LILRB3	CD300C	Q08708	790
LILRB3	CD22	P20273	659
LILRB3	RNASE2	P10153	622
LILRB3	HLA-F	P30511	532
LILRB3	CD79A	P11912	527
LILRB3	BLNK	Q8WV28	510
LILRB3	TYROBP	O43914	507
LILRB3	HLA-E	P13747	470
LILRB3	CFLAR	O15519	433
LILRB3	FCAR	P24071	430
LILRB3	DNTT	P04053	427
LILRB3	THBD	P07204	424
LILRB3	EBF1	Q9UH73	423
LILRB3	XBP1	P17861	421
LILRB3	RPS9	P46781	410

IntAct

15 interactions, top by confidence:

A	B	Type	Score
LILRB3	KRT18	psi-mi:“MI:0914”(association)	0.430
LILRB3	KRT8	psi-mi:“MI:0914”(association)	0.430
LILRB3	PTPN6	psi-mi:“MI:0915”(physical association)	0.400
PTPN6	LILRB3	psi-mi:“MI:0915”(physical association)	0.400
BTNL8	LILRB3	psi-mi:“MI:0915”(physical association)	0.400
	LILRB3	psi-mi:“MI:0915”(physical association)	0.400
MOG	LILRB3	psi-mi:“MI:0915”(physical association)	0.400
LILRB3	MPZ	psi-mi:“MI:0915”(physical association)	0.400
LILRB3	TNFRSF12A	psi-mi:“MI:0915”(physical association)	0.400
	LILRB3	psi-mi:“MI:0915”(physical association)	0.000

ESM2 similar proteins: A0A0K2S4Q6, A2A7V7, A6NI73, A8K4G0, O43699, O75019, O75022, O75023, O75871, O76036, P0C191, P20138, P24071, P40198, P59901, P80943, Q08708, Q13410, Q28110, Q3U497, Q496F6, Q64JA4, Q6GTX8, Q6ISS4, Q6PI73, Q6UXZ3, Q7TSN2, Q863H2, Q8C567, Q8K249, Q8MJZ2, Q8MJZ7, Q8N149, Q8N423, Q8N6C8, Q8NHJ6, Q8NHL6, Q8VBT3, Q8VCH2, Q95JB9

Diamond homologs: A0A0G2KBC9, A6NI73, C0HJX2, C0HJX3, D3ZQX2, O75019, O75022, O75023, O76036, P0C191, P24071, P43626, P43629, P43630, P59901, P83556, P97484, Q14943, Q14954, Q61450, Q64281, Q6GTX8, Q6ISS4, Q6PI73, Q7TQA1, Q863H2, Q8C567, Q8IYS5, Q8MJZ2, Q8MJZ7, Q8N109, Q8N149, Q8N423, Q8N6C8, Q8N743, Q8NHJ6, Q8NHK3, Q8NHL6, Q95JB9, Q9HCN6

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

127 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	96
Likely benign	15
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

2187 predictions. Top by Δscore:

Variant	Effect	Δscore
19:54217236:CAGC:C	acceptor_gain	1.0000
19:54217237:AGCCT:A	acceptor_loss	1.0000
19:54217238:GC:G	acceptor_gain	1.0000
19:54217238:GCCTG:G	acceptor_loss	1.0000
19:54217239:CC:C	acceptor_gain	1.0000
19:54217239:CCTG:C	acceptor_loss	1.0000
19:54217240:C:CC	acceptor_gain	1.0000
19:54217240:CTGCA:C	acceptor_loss	1.0000
19:54217314:CTCA:C	donor_loss	1.0000
19:54217315:TCAC:T	donor_loss	1.0000
19:54217316:CACCT:C	donor_loss	1.0000
19:54217317:A:AC	donor_gain	1.0000
19:54217317:A:AT	donor_loss	1.0000
19:54217318:C:CC	donor_gain	1.0000
19:54217318:CCT:C	donor_gain	1.0000
19:54217318:CCTCA:C	donor_gain	1.0000
19:54217344:TCC:T	donor_gain	1.0000
19:54217473:CTCTG:C	acceptor_gain	1.0000
19:54217474:TCTG:T	acceptor_loss	1.0000
19:54217475:CTG:C	acceptor_gain	1.0000
19:54217476:TG:T	acceptor_gain	1.0000
19:54217477:GCTG:G	acceptor_loss	1.0000
19:54217478:C:CC	acceptor_gain	1.0000
19:54217479:T:A	acceptor_loss	1.0000
19:54218636:T:TA	donor_gain	1.0000
19:54218643:A:AC	donor_gain	1.0000
19:54218644:C:CC	donor_gain	1.0000
19:54218764:T:TA	donor_gain	1.0000
19:54219125:TCAC:T	donor_loss	1.0000
19:54219126:CACC:C	donor_loss	1.0000

AlphaMissense

1012 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000122357 (19:54217595 C>A,T), RS1000270962 (19:54219632 C>T), RS1000860231 (19:54215812 C>G), RS1001012017 (19:54218618 C>G), RS1002063044 (19:54218938 A>G), RS1002066934 (19:54217723 C>T), RS1002264870 (19:54216894 T>A,C,G), RS1002658153 (19:54218881 A>C), RS1002722103 (19:54216755 C>T), RS1003015521 (19:54216958 C>G,T), RS1004965931 (19:54215907 C>T), RS1005191721 (19:54217862 C>T), RS1005710436 (19:54217651 C>T), RS1006044366 (19:54216498 G>T), RS1006104722 (19:54216315 T>C)

Disease associations

OMIM: gene MIM:604820 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

4 associations (top):

Study	Trait	p-value
GCST006575_26	Takayasu arteritis	2.000000e-08
GCST006575_50	Takayasu arteritis	4.000000e-08
GCST008362_34	Birth weight	1.000000e-11
GCST90002393_673	Monocyte count	3.000000e-10

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0004344	birth weight
EFO:0005091	monocyte count

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

20 total (human), top 20 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Methotrexate	decreases expression	2
GSK-J4	increases expression	1
triphenyl phosphate	affects expression	1
di-n-butylphosphoric acid	affects expression	1
azoxystrobin	decreases expression	1
chloropicrin	increases expression	1
4-chloro-N-((4-(1,1-dimethylethyl)phenyl)methyl)-3-ethyl-1-methyl-1H-pyrazole-5-carboxamide	decreases expression	1
pyrimidifen	decreases expression	1
ICG 001	increases expression	1
picoxystrobin	decreases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	increases expression	1
Benzo(a)pyrene	decreases expression	1
Nickel	increases expression	1
Rotenone	decreases expression	1
Tretinoin	increases expression	1
Valproic Acid	decreases expression, increases methylation	1
Zidovudine	affects cotreatment, increases expression	1
Aflatoxin B1	increases methylation	1
Antirheumatic Agents	decreases expression	1
Cadmium Chloride	increases expression	1

Cellosaurus cell lines

2 cell lines: 1 spontaneously immortalized cell line, 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_E6R1	Genomeditech CHO-K1 H_LILRB3(ILT5)	Spontaneously immortalized cell line	Female
CVCL_E6UF	Genomeditech HEK-293 H_LILRB3(ILT5)	Transformed cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.